Vaniqa--eflornithine 13.9% cream.
Eflornithine HCl 13.9% cream is the first topical prescription treatment to be approved by the US FDA for the reduction of unwanted facial hair in women. It irreversibly inhibits ornithine decarboxylase (ODC), an enzyme that catalyzes the rate-limiting step for follicular polyamine synthesis, which is necessary for hair growth. In clinical trials eflornithine cream slowed the growth of unwanted facial hair in up to 60% of women. Improvement occurs gradually over a period of 4-8 weeks or longer. Most reported adverse reactions consisted of minor skin irritation.
Shapiro
J
J
Hair Research and Treatment Centre, and Division of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada.
Lui
H
H
D000287:Administration, Topical; D002986:Clinical Trials as Topic; D000518:Eflornithine / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005145:Face; D005260:Female; D006204:Hair Removal / Q000379:methods*; D006801:Humans
D004791:Enzyme Inhibitors; D000518:Eflornithine